OBI Pharma’s Board of Directors approves the announcement of the Company’s 2016 individual and consolidated financial statements

Supplemental Information: OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)
January 26, 2017
Announcement by the Company’s Board of Directors to convene the 2016 Annual General Shareholders’ meeting
March 9, 2017
  1. Date of the Event: 9 Mar 2017
  2. Company Name: OBI Pharma, Inc
  3. Relationship to the Company (enter “Parent” or “Subsidiary”: Parent
  4. Reciprocal shareholding ratios: N/A
  5. Reason for the Event: The Company’s 2016 individual and consolidated financial statements were
    approved by the board of directors. Essential financial items are presented below.

    • From the 2016 Individual Financial Statement
      – Operating loss:                                         (NT$ 1,110,256,000)
      – Total comprehensive loss for the period: (NT$ 1,111,256,000)
      – Loss Per Share (in dollars):                                     (NT$ 6.51)
    • From the 2016 Consolidated Financial Statement
      – Operating loss:                                         (NT$ 1,112,470,000)
      – Total comprehensive loss for the period: (NT$ 1,111,256,000)
      – Loss Per Share (in dollars):                                     (NT$ 6.51)
  6. Countermeasures: N/A
  7. Any other matters that need to be specified: None